Johnson & Johnson

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Johnson & Johnson 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About JNJ

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. 

CEO
Joaquin Duato
CEOJoaquin Duato
Employees
140,800
Employees140,800
Headquarters
New Brunswick, New Jersey
HeadquartersNew Brunswick, New Jersey
Founded
1887
Founded1887
Employees
140,800
Employees140,800

JNJ Key Statistics

Market cap
649.01B
Market cap649.01B
Price-Earnings ratio
31.20
Price-Earnings ratio31.20
Dividend yield
1.96%
Dividend yield1.96%
Average volume
6.44M
Average volume6.44M
High today
$272.14
High today$272.14
Low today
$266.54
Low today$266.54
Open price
$269.71
Open price$269.71
Volume
6.64M
Volume6.64M
52 Week high
$281.07
52 Week high$281.07
52 Week low
$175.74
52 Week low$175.74

Stock Snapshot

The current Johnson & Johnson(JNJ) stock price is $268.71, with a market capitalization of 649.01B. The stock trades at a price-to-earnings (P/E) ratio of 31.20 and offers a dividend yield of 1.96%.

During the trading session on 2026-09-24, Johnson & Johnson(JNJ) shares reached a daily high of $272.14 and a low of $266.54. At a current price of $268.71, the stock is +0.8% higher than the low and still -1.3% under the high.

Trading volume for Johnson & Johnson(JNJ) stock has reached 6.64M, versus its average volume of 6.44M.

Over the past 52 weeks, Johnson & Johnson(JNJ) stock has traded between a high of $281.07 and a low of $175.74.

Over the past 52 weeks, Johnson & Johnson(JNJ) stock has traded between a high of $281.07 and a low of $175.74.

JNJ News

Simply Wall St 28m
Can Johnson & Johnson Justify A Discount To Cash Flow?

has delivered a powerful run over the past few years, and with the stock now near US$269, investors are increasingly asking whether that price is fully backed b...

Can Johnson & Johnson Justify A Discount To Cash Flow?
New York Times 13h
J.J. McCarthy, Mac Jones, Garoppolo and 4 other names for NFL teams in need of a quarterback - The New York Times

...

J.J. McCarthy, Mac Jones, Garoppolo and 4 other names for NFL teams in need of a quarterback - The New York Times
TipRanks 14h
Johnson & Johnson: Phase 3 MajesTEC-3 study shows ‘sustained’ disease control

Johnson & Johnson announced new data from the Phase 3 MajesTEC-3 study showing sustained disease control and survival with TECVAYLI plus DARZALEX FASPRO in pati...

Analyst ratings

70%

of 27 ratings
Buy
70.4%
Hold
22.2%
Sell
7.4%

More JNJ News

TipRanks 2d
Michael Yee Reiterates Buy on JNJ, Maintains $320 Price Target on Caplyta’s Strong Bipolar Mania Prospects

Analyst Michael Yee from UBS maintained a Buy rating on Johnson & Johnson and keeping the price target at $320.00. Michael Yee has given his Buy rating due to...

Simply Wall St 2d
Is Johnson & Johnson Fully Priced Following Caplyta Data And Portfolio Change Talk?

Johnson & Johnson (JNJ) is back in focus after new Phase 3 data for Caplyta in bipolar I mania, with investors weighing how this potential label expansion inter...

Is Johnson & Johnson Fully Priced Following Caplyta Data And Portfolio Change Talk?
Nasdaq 2d
Johnson & Johnson May Offload Its Orthopedics Unit for $20 Billion -- and Investors Shouldn't Miss What That Could Signal

Key Points Johnson & Johnson announced plans to spin off its orthopedics business in late 2025. In early 2026, J&J was reported to be in talks with private eq...

Johnson & Johnson May Offload Its Orthopedics Unit for $20 Billion -- and Investors Shouldn't Miss What That Could Signal
Nasdaq 3d
The Investing Playbook for Retirees Who Can't Afford to Lose

The Investing Playbook for Retirees Who Can't Afford to Lose Key Points Remaining diversified is one of the best ways to reduce risk. A cash fund can prevent y...

The Investing Playbook for Retirees Who Can't Afford to Lose
TipRanks 3d
J&J says Caplyta Phase 3 study in bipolar I met primary endpoint

Johnson & Johnson announced topline results from the Phase 3 study evaluating Caplyta for the treatment of manic episodes with or without mixed features in adul...

TipRanks 3d
Johnson & Johnson announces ‘positive’ results from Phase 3 trial of Caplyta

Johnson & Johnson announced positive topline results from the pivotal Phase 3 study evaluating Caplyta for the treatment of manic episodes with or without mixed...

Simply Wall St 6d
Johnson & Johnson Advances Sjögren's Therapies With New Biomarker Trial Data

Johnson & Johnson (NYSE: JNJ) reported new biomarker findings tied to its targeted therapies for Sjögren's syndrome in ongoing trials. The pharmaceutical segme...

Johnson & Johnson Advances Sjögren's Therapies With New Biomarker Trial Data

People also own

Based on the portfolios of people who own JNJ. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.